• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Gly719Ser (c.2155G>A); ClinVar=VCV000016612; Zygosity=Unspecified (PubMed=16105816).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.His214Arg (c.641A>G); ClinVar=VCV000376615; Zygosity=Unspecified (PubMed=10536175; PubMed=20557307).
  

PubMed=758928; DOI=10.1038/bjc.1979.3; PMCID=PMC2009802
Kinjo M., Oka K., Naito S., Kohga S., Tanaka K., Oboshi S., Hayata Y., Yasumoto K.
Thromboplastic and fibrinolytic activities of cultured human cancer cell lines.
Br. J. Cancer 39:15-23(1979)

DOI=10.5795/jjscc.24.451
Tsumuraya M., Nakajima T., Terasaki T., Kodama T., Shimosato Y., Higuchi H., Uei Y.
Analysis of LDH isoenzyme patterns in cell lines of the small cell carcinoma (lung) and retinoblastoma.
Nihon Rinsho Saibo Gakkai Zasshi 24:451-456(1985)

PubMed=3731100
Hanai N., Shitara K., Yoshida H.
Generation of monoclonal antibodies against human lung squamous cell carcinoma and adenocarcinoma using mice rendered tolerant to normal human lung.
Cancer Res. 46:4438-4443(1986)

PubMed=2168285
Kanzawa F., Sugimoto Y., Minato K., Kasahara K., Bungo M., Nakagawa K., Fujiwara Y., Liu L.F., Saijo N.
Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.
Cancer Res. 50:5919-5924(1990)

PubMed=1847845; DOI=10.1007/BF00685110
Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., Ohmori T., Saijo N.
Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Cancer Chemother. Pharmacol. 27:263-270(1991)

PubMed=1332703; DOI=10.1016/0006-291X(92)91094-7
Kubota N., Kanzawa F., Nishio K., Takeda Y., Ohmori T., Fujiwara Y., Terashima Y., Saijo N.
Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line.
Biochem. Biophys. Res. Commun. 188:571-577(1992)

PubMed=10536175; DOI=10.3892/ijo.15.5.927
Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.
Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.
Int. J. Oncol. 15:927-934(1999)

PubMed=11005564; DOI=10.1038/sj.neo.7900094; PMCID=PMC1550293
Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M., Yokota J.
Mutation and expression of the DCC gene in human lung cancer.
Neoplasia 2:300-305(2000)

PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331
Nagai Y., Miyazawa H., Hu Q., Tanaka T., Udagawa K., Kato M., Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Cancer Res. 65:7276-7282(2005)

PubMed=19472407; DOI=10.1002/humu.21028; PMCID=PMC2900846
Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
A gene-alteration profile of human lung cancer cell lines.
Hum. Mutat. 30:1199-1206(2009)

PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x; PMCID=PMC11158680
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Cancer Sci. 101:1891-1896(2010)